Head over to the Lancet and check out the just published HPS data in Lancet: C-reactive protein concentration and the vascular benefi ts of statin therapy: an analysis of 20 536 patients in the Heart Protection Study:
Interpretation Evidence from this large-scale randomised trial does not lend support to the hypothesis that baseline CRP concentration modifi es the vascular benefi ts of statin therapy materially.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62174-5/abstract
Also see editorial by JP Despres
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62316-1/fulltext#article_upsell
Sooner or later they will all figure out that it is apoB and LDL-P that predicts what statins will or will not do. Why does no one, other than Alan Sniderman and his many followers (including me) ever mention the pretty ugly apoB data in JUPITER in all those folks with normal LDL-C. We need to see the NMR data from HPS that Dr Virgil Brown tlaked about in the IAS meeting in Boston two years ago. One day we will hopefully also have the JUPITER NMR data. Then we can all move on.
ldl-p (11)
triglycerides (9)
women (6)
lipoproteins (5)
hdl (4)
diabetes (4)
niacin (3)
hdls (3)
hdl-p (3)
fenofibrate (3)
acids (3)
apob (3)
size (2)
fatty (2)
lp(a) (2)
guidelines (2)
testing (2)
insulin (2)
resistance (2)
lp(a)-c (2)
